Dr. Reddy’s Laboratories has entered into a distribution agreement under which Dr. Reddy’s will promote and distribute Takeda’s dengue vaccine, QDENGA, across India’s private market for pediatric and adult vaccination in India. Subject to completion of applicable processes with local authorities, the vaccine is anticipated to become available in the first half of 2027.

The collaboration follows the approval of QDENGA’s Marketing Authorisation (MA) by India’s Central Drugs Standard Control Organization (CDSCO) in July 2026 for individuals aged 4-60 years.

As India’s first approved dengue vaccine, the approval marks an important milestone in the country’s efforts to strengthen dengue prevention and management.

Takeda is committed to supporting the country’s long-term dengue control efforts and enabling broad, equitable access to QDENGA. While inclusion in India’s public immunisation program remains an important long-term ambition, private market availability through Dr. Reddy’s will provide a pathway for eligible individuals to access the vaccine once it becomes available.

Through the collaboration, the two comapnies will support healthcare-professional engagement, disease awareness, promotion and distribution of QDENGA across India’s private market for pediatric and adult vaccination, in accordance with applicable regulatory requirements.

MV Ramana, CEO—Global Generics, Dr. Reddy’s Laboratories, said, “As the second-largest vaccine player in India, we believe the introduction of India’s first approved dengue vaccine is an important development for the country’s healthcare landscape. Through our collaboration with Takeda, we look forward to making QDENGA available to eligible individuals and contributing to efforts aimed at addressing the country’s dengue burden.

Dengue remains a significant and evolving public-health challenge in India, with reported cases increasing 11-fold over the past 2 decades. According to a nationwide dengue surveillance study conducted by the Virus Research and Diagnostic Laboratory of the Indian Council of Medical Research (ICMR), all 4 dengue virus serotypes (DENV-1 to DENV-4) are co-circulating across multiple regions in India, with 1 in 14, patients being infected with multiple dengue serotypes concurrently.

With dengue cases occurring year-round across India, dengue prevention and management is an urgent public-health priority.

Dr. Mahender Nayak, Head of Intercontinental Markets, International Business Unit Takeda, said, “Takeda is committed to supporting India’s evolving healthcare needs and expanding access to dengue vaccination. We welcome the recent Parliamentary Committee on Health’s recommendation to consider dengue vaccine for the Universal Immunisation Program. This reflects the growing recognition of dengue as a significant public health challenge. In parallel, our private-market collaboration with Dr. Reddy’s will help enable timely private-market access for eligible individuals once QDENGA becomes available in India.”